Business Context and Reporting Period
This Form 8-K Current Report was filed by Cerulean Pharma Inc. on October 14, 2016. The filing discloses the entry into a Material Definitive Agreement with Aspire Capital Fund, LLC. Note: The request metadata references "Dare Bioscience, Inc.," but the filing text explicitly identifies the registrant as Cerulean Pharma Inc.
Key Financial Metrics and Transaction Details
- Agreement Type: Common Stock Purchase Agreement and Registration Rights Agreement.
- Total Commitment: Aspire Capital is committed to purchase up to $20.0 million of common stock over a 24-month term.
- Initial Proceeds: An immediate sale of 800,000 shares at $1.25 per share generated $1.0 million in proceeds.
- Commitment Shares: The Company issued 700,000 shares to Aspire Capital as consideration for entering the agreement.
- Remaining Capacity: Up to $19.0 million remains available for future sales under the agreement.
- Use of Proceeds: Working capital and general corporate purposes.
- Financial Covenants: None. There are no financial or business covenants, restrictions on future funding, or limitations on the use of proceeds.
Material Changes and Pricing Mechanics
The filing establishes a new equity financing facility. The pricing mechanism for future sales is designed to protect the investor while allowing the company to control the timing of sales:
- Purchase Price: The lesser of (1) the lowest sale price on the purchase date, or (2) the arithmetic average of the three lowest closing sale prices during the ten consecutive trading days preceding the purchase date.
- Daily Limits: The Company may direct purchases of up to 200,000 shares per trading day (increasable to 2,200,000 by mutual agreement), with a maximum daily purchase price of $300,000 unless otherwise agreed.
- VWAP Option: If the closing price is above $0.50, the Company may issue a Volume-Weighted Average Price (VWAP) notice for up to 30% of the day's trading volume, priced at the lesser of the closing price or 97% of the VWAP.
- Price Floor: No sales may occur if the closing sale price is less than $0.25.
Outlook, Risks, and Management Commentary
- Management Control: The Company retains sole discretion over the timing and amount of sales. Aspire Capital has no right to require sales but is obligated to purchase as directed.
- Termination Rights: The Company may terminate the agreement at any time without cost. Aspire Capital may terminate only upon specified events of default (e.g., lack of registration statement, delisting, bankruptcy).
- Short-Selling Restriction: Aspire Capital is prohibited from engaging in direct or indirect short-selling or hedging of the Company's stock during the term of the agreement.
- Risks: The filing notes that the summary is incomplete and directs readers to the full text of the exhibits. The primary risk involves potential dilution to existing shareholders as the Company exercises its right to sell up to $20 million of stock.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess immediate dilution from the 800,000 initial shares and 700,000 commitment shares.
- Review the effective shelf registration statement (Form S-3, File No. 333-206396) referenced in the filing.
- Monitor future 8-K filings for "Purchase Notices" to track the pace of capital raising and the specific prices at which shares are sold.
- Confirm the Company's current cash position to determine the urgency of utilizing the remaining $19.0 million commitment.